Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

Compare
130.92
+2.42
+(1.88%)
At close: April 2 at 4:00:00 PM EDT
127.99
-2.93
(-2.24%)
Pre-Market: 4:14:47 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
634,439
634,439
632,362
801,536
670,534
Cost of Revenue
359,794
359,794
353,922
345,830
279,280
Gross Profit
274,645
274,645
278,440
455,706
391,254
Operating Expense
306,568
306,568
261,306
259,765
218,140
Operating Income
-31,923
-31,923
17,134
195,941
173,114
Net Non Operating Interest Income Expense
-22,574
-22,574
-10,578
-2,977
-12,714
Other Income Expense
27,462
27,462
50,151
26,176
-6,857
Pretax Income
-27,035
-27,035
56,707
219,140
153,543
Tax Provision
-1,521
-1,521
21,111
33,181
25,252
Net Income Common Stockholders
-25,514
-25,514
35,596
185,959
128,291
Diluted NI Available to Com Stockholders
-25,514
-25,514
35,596
185,959
128,291
Basic EPS
-0.03
-0.46
0.64
3.35
2.33
Diluted EPS
-0.03
-0.46
0.63
3.24
2.24
Basic Average Shares
55,876
55,937
55,720
55,460.23
55,015.18
Diluted Average Shares
55,913.50
55,937
56,377
57,455.28
57,264.27
Total Operating Income as Reported
-35,114
-35,114
47,703
224,670
167,249
Total Expenses
666,362
666,362
615,228
605,595
497,420
Net Income from Continuing & Discontinued Operation
-25,514
-25,514
35,596
185,959
128,291
Normalized Income
-56,322.38
-56,322.38
9,202.42
155,643.76
133,047
Interest Expense
20,731
20,731
2,503
1,162
11,278
Net Interest Income
-22,574
-22,574
-10,578
-2,977
-12,714
EBIT
-6,304
-6,304
59,210
220,302
164,821
EBITDA
80,258
80,258
145,324
277,314
203,268
Reconciled Cost of Revenue
359,794
359,794
353,922
345,830
279,280
Reconciled Depreciation
86,562
86,562
86,114
57,012
38,447
Net Income from Continuing Operation Net Minority Interest
-25,514
-25,514
35,596
185,959
128,291
Total Unusual Items Excluding Goodwill
32,636
32,636
42,028
35,707
-5,689
Total Unusual Items
32,636
32,636
42,028
35,707
-5,689
Normalized EBITDA
47,622
47,622
103,296
241,607
208,957
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,827.62
1,827.62
15,634.42
5,391.76
-933
12/31/2021 - 4/29/1986

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

STVN Stevanato Group S.p.A.
20.97
+0.43%
 
ICUI ICU Medical, Inc.
140.38
+1.87%
 
WST West Pharmaceutical Services, Inc.
221.50
+0.61%
 
NVST Envista Holdings Corporation
17.51
+2.40%
 
AVTR Avantor, Inc.
16.29
+3.10%
 
DIM.PA Sartorius Stedim Biotech S.A.
182.75
+0.88%
 
ATR AptarGroup, Inc.
150.53
+0.96%
 
BLFS BioLife Solutions, Inc.
23.78
+4.16%
 
ALGN Align Technology, Inc.
163.98
+3.73%
 
MMSI Merit Medical Systems, Inc.
107.04
+1.51%